[Atorvastatin in primary prevention].
Statins are one of the most widely used drugs in medical treatment and have been shown to prevent cardiovascular disease or reduce risk in a large number of studies. Although there is a general class effect, there are differences with regard to structure and efficacy between these agents. Among these agents, atorvastatin is a potent statin whose efficacy has been demonstrated in many clinical trials. Despite the presence of numerous clinical studies, data on atorvastatin related to primary prevention are limited compared to secondary prevention. In this article, clinical results of primary prevention trials with atorvastatin and data on its cost-effectiveness are reviewed. It is concluded that atorvastatin has a role in primary prevention and the cost of its use seems to be lower than commonly accepted cost-effectiveness thresholds.
Kültürsay
Hakan
H
Department of Cardiology, Medicine Faculty of Ege University, Izmir, Turkey. hakan.kultursay@ege.edu.tr
D000069059:Atorvastatin; D002318:Cardiovascular Diseases / Q000191:economics / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D006538:Heptanoic Acids / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000191:economics / Q000627:therapeutic use*; D011322:Primary Prevention / Q000191:economics; D011758:Pyrroles / Q000191:economics / Q000627:therapeutic use*
D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin